In a groundbreaking development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), the Phase 3 SEQUOIA-HCM trial has demonstrated that aficamten, an investigational oral selective

In a groundbreaking analysis of the STEPHFpEF programme, researchers have discovered that semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), not only improves heart failure-related

In a thought-provoking presentation, Dr. Milton Packer, a renowned expert in the field of cardiology, shed light on the groundbreaking findings from recent SGLT2 inhibitor

Professor Mark Petrie from the University of Glasgow and Glasgow Royal Infirmary presented an overview of the future directions and novel treatment strategies for heart

In a groundbreaking study, researchers have investigated the potential of CRD-740, a PDE9 inhibitor, as a treatment for chronic heart failure. The Phase 2, randomized,

The PARACOR-19 randomized controlled trial (RCT) has investigated the effects of sacubitril/ valsartan on markers of cardiac injury, inflammation, structure, and function in patients who

A recent study from the Spanish Society of Cardiology-Excellence Heart Failure registry has shed light on the substantial impact of advanced chronic kidney disease (CKD)

Inflammation has been recognized as a crucial factor in the development and progression of heart failure (HF). A recent single-center study involving 4,043 patients discharged

In a recent retrospective analysis of the IRONMAN trial, researchers have found that the efficacy of intravenous (IV) ferric derisomaltose (FDI) is similar in both